title: Liver transplantation at Mount Sinai.
abstract: Nearly 2000 liver transplants have been performed over the past 12 years at Mount Sinai, with a recent exponential growth in living donor surgeries. Living-donor liver transplantation has emerged as an important option for our patients with end-stage liver disease. We are only beginning to recognize fully the advantages that 'scheduled' liver transplantation can offer. In this era of severe cadaver organ shortages, living donation offers patients the option of liver replacement in a timely fashion, before life-threatening complications of hepatic failure and/or carcinoma progression prohibit transplantation. The next era of transplantation at Mount Sinai will bring significant increases in the number of transplants performed with living donors, with projections of over 50% of the total transplants each year expected to involve living donations. We are committed to offering this option while recognizing that donor safety remains paramount and cannot be overemphasized. Proper donor and recipient selection, as well as surgical experience are imperative to success with this technically demanding procedure. Recurrent disease after transplantation, particularly with hepatitis C, remains a challenge clinically. Further investigations into the pathogenesis of the rapid progression of recurrent hepatitis C need to be addressed. Living donor transplantation could be an important option for these patients and would allow timely transplantation and the potential for improved survival in patients with hepatocellular carcinoma.
authors.affiliation: Recanati/Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
authors.forename: L
authors.initials: L
authors.lastname: Kim-Schluger
authors.forename: S S
authors.initials: SS
authors.lastname: Florman
authors.forename: G
authors.initials: G
authors.lastname: Gondolesi
authors.forename: S
authors.initials: S
authors.lastname: Emre
authors.forename: P A
authors.initials: PA
authors.lastname: Sheiner
authors.forename: T M
authors.initials: TM
authors.lastname: Fishbein
authors.forename: M E
authors.initials: ME
authors.lastname: Schwartz
authors.forename: C M
authors.initials: CM
authors.lastname: Miller
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000601:surgery; D002648:Child; D006085:Graft Survival; D006526:Hepatitis C / Q000601:surgery; D019693:Hepatitis, Autoimmune / Q000601:surgery; D006786:Hospitals, Urban; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation / Q000401:mortality / Q000706:statistics & numerical data; D019520:Living Donors / Q000523:psychology; D009519:New York City / Q000453:epidemiology; D011584:Psychology; D012008:Recurrence; D015996:Survival Rate; D009927:Tissue and Organ Procurement